Loading...

AMLX AMYLYX PHARMACEUTICALS INC Expansion Plans 8-K Filing

MYLY

MLX

AMYLYX PHARMACEUTICALS INC

(AMLX)

2026 8-K

Corporate Presentation Update

Financial Results

New Drug Candidate

Financial Results Update

Stock Offering Announcement

Program Discontinuation

Financial Statements

Financial Statements

Financial Results

Collaboration Announcement

Financial Results

Clinical Trial Results

Financial Results Announcement

Acquisition of Avexitide Asset

Asset Purchase Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Management Change

Financial Results Announcement

Financial Results Announcement

Conference Call

Rejection of Marketing Auth...

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Conference Presentation

External Links:

On January 8, 2026, Amylyx Pharmaceuticals announced AMX0318 as a development candidate for post-bariatric hypoglycemia, with potential payments exceeding $50 million to their research partner Gubra, including an immediate $4 million milestone.

AI Assistant

AMYLYX PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.